IGF-1: How to Interpret Your Result

The useful question for most readers is not "is my IGF-1 normal" but "does my IGF-1 make sense given my age, my medications, and my clinical situation, or does it need a repeat test and a confounder check before anyone acts on it." Isolated single values, drawn on different assay platforms, or drawn during illness or oral estrogen use, are the most common reason IGF-1 gets over-interpreted.

What IGF-1 Actually Measures

IGF-1 is a peptide hormone produced mainly by the liver in response to GH stimulation. Testing IGF-1 approximates the integrated output of the GH axis over roughly the prior day, rather than capturing a single GH pulse that lasts only minutes [1]. That is the whole reason IGF-1 is used clinically instead of GH itself.

GH is secreted in bursts, with the largest pulses during slow-wave sleep. A random GH level in the same healthy person can range from undetectable to double digits within hours, which makes random GH testing clinically unreliable for most purposes. IGF-1 does not swing that way. The Endocrine Society's clinical practice guideline on adult GH deficiency identifies serum IGF-1 as the recommended initial screening measurement for suspected GH disorders [2]. Results are usually reported in ng/mL; some labs report nmol/L, where 1 ng/mL is approximately 0.131 nmol/L.

Three things determine whether a number is meaningful: the reader's age, sex-related factors such as oral estrogen use, and the specific assay platform the lab used, since platforms are not fully harmonized and can report meaningfully different values for the same blood sample [3]. Switching labs mid-treatment is a common, avoidable source of false alarms.

Normal IGF-1 ranges by age

IGF-1 reference ranges are age-banded, not a single cutoff, and they decline through adulthood after peaking around puberty [4][5]. The bands below are the kind of age-stratified adult reference intervals commonly published by clinical laboratories; your own lab's insert is the authoritative range for your specific result, since assay platforms differ.

• Ages 18 to 25: roughly 116 to 358 ng/mL
• Ages 26 to 35: roughly 117 to 329 ng/mL
• Ages 36 to 45: roughly 101 to 267 ng/mL
• Ages 46 to 55: roughly 87 to 238 ng/mL
• Ages 56 to 65: roughly 75 to 212 ng/mL
• Ages 66 to 75: roughly 64 to 188 ng/mL
• Ages 76 and older: roughly 48 to 166 ng/mL

A 55-year-old with an IGF-1 of 95 ng/mL is within normal limits for that age band, even though the same number in a 20-year-old would prompt further evaluation. Adolescents in peak growth can show markedly elevated values that are entirely physiologic for that life stage [5].

Sex differences are smaller than age differences but are not trivial. Premenopausal women on oral estrogen (oral contraceptives or oral hormone replacement) tend to run lower than age-matched men or than women on transdermal estrogen, because oral estrogen suppresses hepatic IGF-1 production through a first-pass liver effect [6]. A "low" IGF-1 in a woman on oral estrogen does not necessarily mean GH deficiency.

What a high IGF-1 means

An IGF-1 above the age-adjusted upper limit raises three main possibilities: acromegaly, exogenous GH or GH-secretagogue peptide use, or an assay artifact.

Acromegaly, caused by a GH-secreting pituitary adenoma, is the diagnosis clinicians most want to exclude because it is rare and commonly under-recognized, with a diagnostic delay from symptom onset that has historically been reported in the range of several years [7]. The Endocrine Society's acromegaly guideline recommends IGF-1 as the initial biochemical test in patients with suggestive features such as enlarging hands and feet, jaw prognathism, or new-onset sleep apnea. If IGF-1 is elevated, the confirmatory step is a 75-gram oral glucose tolerance test; in healthy people GH suppresses to very low levels after glucose loading, and failure to suppress supports the diagnosis [8]. This is a guideline-recommended diagnostic pathway, not something a reader should attempt to self-interpret from a single lab report.

In patients on GH replacement or on a GH-releasing peptide (examples include CJC-1295, ipamorelin, and tesamorelin), a high IGF-1 usually means the dose is higher than needed. The Endocrine Society guideline supports targeting the upper half of the age-adjusted normal range rather than the ceiling or above it [2]. Pushing IGF-1 above the normal range is associated, in observational data, with fluid retention, joint pain, and insulin resistance, and with the population-level cancer-risk signals described below, none of which is a reason to accept an out-of-range IGF-1 as a therapy goal.

A note on peptide status: ipamorelin, CJC-1295, and sermorelin are GH secretagogues that are not FDA-approved medications for GH deficiency or for longevity or aesthetic use; where they are used clinically, that use is off-label or through compounded preparations, and the evidence base for long-term outcomes is thinner than for the guideline-based indications above. Tesamorelin is the one FDA-approved GH-releasing hormone analog in this group, approved specifically for HIV-associated lipodystrophy, and it reliably raises IGF-1 in that population according to its pivotal trial [16].

On cancer risk, a pooled analysis of prospective cohort data on circulating IGF-1 and breast cancer risk in women found a modest, statistically significant association between higher IGF-1 and breast cancer risk, particularly in premenopausal women [9]. Other observational cohorts have reported similarly modest positive associations between higher circulating IGF-1 and colorectal or prostate cancer risk; the exact effect size for those specific cancers is not confirmed within the sources checked for this article and should be verified against the primary literature before being cited as a precise number. What the evidence supports clearly is a population-level, non-causal association, not proof that therapeutically optimizing IGF-1 within the normal range causes cancer. This nuance is exactly why clinicians target the middle of the range rather than the ceiling.

What a low IGF-1 means

A low IGF-1, below the age-adjusted lower limit, points toward reduced GH secretion, poor nutritional status, liver dysfunction, or a combination of these.

Adult GH deficiency most often follows pituitary surgery, radiation, traumatic brain injury, or is idiopathic. In patients with already-established pituitary disease, an IGF-1 below the lower limit of normal for age and sex has high reported specificity for severe GH deficiency, according to endocrine society guidance [10]. In patients without known pituitary disease, a low IGF-1 alone is less diagnostic and typically needs confirmatory GH stimulation testing (insulin tolerance test, glucagon stimulation, or macimorelin) before a diagnosis is made.

Malnutrition suppresses IGF-1 because hepatic production depends on adequate protein and caloric intake. Patients with anorexia nervosa commonly show markedly low IGF-1 regardless of age. Sustained caloric restriction in otherwise healthy adults also lowers IGF-1, an effect some longevity researchers view as potentially protective and others view simply as a marker of reduced anabolic drive; human calorie-restriction studies have documented measurable reductions in IGF-1 with sustained restriction, though exact percentages vary by study design and duration [11].

Liver disease suppresses IGF-1 because hepatocytes are the primary production site, and IGF-1 correlates inversely with the severity of liver dysfunction in cirrhosis [12]. An unexpectedly low IGF-1 in someone without known pituitary disease should prompt a look at liver function.

Hypothyroidism, poorly controlled type 1 diabetes, chronic kidney disease, and high-dose glucocorticoid use also suppress IGF-1 and need to be considered as confounders before concluding GH deficiency [2].

How to raise IGF-1

What actually helps depends entirely on the cause. GH-axis interventions will not fix a nutritional problem, and nutritional fixes will not correct true GH deficiency.

Protein intake. Adequate amino acid delivery to the liver is required for IGF-1 production. Research on nutritional predictors of IGF-1 has linked lower protein intake to lower IGF-1 levels in older adults, independent of total calories [13]. Increasing protein toward roughly 1.0 to 1.2 g/kg/day is a reasonable, low-risk step for someone whose intake is currently below general adequacy thresholds, though the exact IGF-1 response varies by individual.

Sleep. Because the largest GH pulses occur in slow-wave sleep, poor sleep quality suppresses GH secretion and, over time, IGF-1. Acute total sleep deprivation has been shown to substantially blunt the next day's GH secretory burst in controlled studies [14].

Resistance training. Resistance exercise acutely stimulates GH release, and chronic resistance training is associated with modestly higher baseline IGF-1 in older adults over months of training, though the effect size is real but not large [15].

GH secretagogue therapy. For confirmed GH deficiency, or for age-related GH decline where a clinician judges pharmacologic treatment appropriate, GH-releasing peptides can raise IGF-1. Tesamorelin's pivotal trial in HIV-associated lipodystrophy documented a substantial average increase in IGF-1 from baseline in that specific population [16]; this is FDA-approved-indication evidence and does not automatically generalize to healthy adults using tesamorelin off-label for other goals. Other secretagogues in this class (ipamorelin, CJC-1295, sermorelin) are not FDA-approved for GH deficiency and are used off-label or as compounded products; their IGF-1 effects are more variable because they depend on the patient's remaining pituitary reserve.

Direct GH replacement. Recombinant human GH remains the guideline standard for diagnosed adult GH deficiency, titrated to bring IGF-1 into the mid-normal range for age rather than to a maximum [2]. Specific starting doses and titration schedules are an individualized prescribing decision between a patient and their treating clinician, not something to self-determine from a lab result.

How to lower IGF-1

Lowering IGF-1 matters clinically in two distinct situations: treating confirmed acromegaly, and correcting an overshoot from GH or peptide therapy.

In acromegaly, first-line medical therapy after surgery typically includes somatostatin analogs such as octreotide LAR or lanreotide, which normalize IGF-1 in a meaningful proportion of patients at conventional doses [8]. Pegvisomant, a GH receptor antagonist, normalizes IGF-1 in a large majority of cases in registry data but does not shrink the pituitary tumor itself [17].

For patients on GH or peptide therapy whose IGF-1 has drifted above the upper limit, the standard response is dose reduction followed by a recheck in 4 to 6 weeks, repeated until the level settles into the upper half of the age-matched range. This should be done under the supervision of the prescribing clinician rather than through self-adjustment.

Diet-based approaches can modestly lower IGF-1 in people without acromegaly. Sustained caloric restriction reduces IGF-1 in controlled human studies [11]. Dairy protein intake is positively associated with circulating IGF-1 across multiple epidemiologic cohorts in Europe, plausibly related to its casein and whey content stimulating hepatic IGF-1 synthesis, though this is an observational association rather than a causal trial finding [18]. Intermittent fasting and time-restricted eating can acutely lower IGF-1, but the sustained effect depends on total caloric and protein intake over time rather than meal timing alone.

Monitoring IGF-1 during GH or peptide therapy

IGF-1 is the primary lab used to judge whether GH or peptide therapy is dosed appropriately. A reasonable monitoring cadence, consistent with Endocrine Society guidance, is a baseline IGF-1 before starting, a recheck 4 to 6 weeks after any dose change, and every 3 to 6 months once stable [2]. The general target for most adults on therapy is the upper half of the age-adjusted normal range, not the ceiling and not above it; exceeding the range is a signal to reduce dose, not a sign the treatment is working harder.

IGFBP-3, the main IGF-1 binding protein, is sometimes ordered alongside IGF-1 but adds limited value in adult evaluation. It is more useful in pediatric GH deficiency, where IGF-1 alone can be less reliable at very low concentrations [10].

Timing matters modestly, not dramatically. Because IGF-1 does not swing across the day the way GH does, most clinicians still recommend a consistent morning, fasting draw simply to reduce noise between serial results.

Patients switching between direct GH replacement and GH-releasing peptides should expect different IGF-1 kinetics. Direct GH replacement produces a dose-dependent, fairly predictable IGF-1 rise. Secretagogue peptides produce a more variable response because they depend on how much functioning pituitary tissue the patient has left; someone with significant pituitary damage may show little IGF-1 response to a secretagogue and may need direct GH instead. This is a clinical judgment call, not something to infer from one lab value.

IGF-1 and longevity: a U-shaped pattern, not a straight line

Population studies generally describe a U-shaped relationship between circulating IGF-1 and mortality, where both the lowest and the highest quintiles of IGF-1 carry higher risk than the middle of the distribution. A meta-analysis of dose-response data across multiple cohorts reported higher cardiovascular mortality risk at the low end of the IGF-1 distribution and higher cancer mortality risk at the high end, with the lowest overall risk in the middle of the range [19]. This is observational, associative evidence; it establishes a pattern worth taking seriously, not a proven causal target.

The practical implication is that clinicians interested in longevity-oriented optimization generally aim for IGF-1 in the middle of the age-adjusted distribution rather than pushing toward either extreme.

Separately, genetic studies of long-lived cohorts, including centenarian offspring, have found some enrichment of IGF-1 receptor variants associated with reduced IGF-1 signaling [20]. Whether pharmacologically lowering IGF-1 in someone without that genetic background reproduces the same longevity association is not established; this is a genetics-and-epidemiology observation, not a treatment recommendation.

Common pitfalls in interpretation

Assay variability. Different immunoassay platforms are not fully harmonized and can report meaningfully different IGF-1 values from the same sample, which international consensus statements have identified as a major barrier to consistent clinical decision-making [3]. Use the same lab and platform for serial monitoring whenever possible.

Oral estrogen. Oral estrogen, unlike transdermal estrogen, suppresses hepatic IGF-1 production through first-pass liver metabolism [6]. A "low" IGF-1 in a woman on oral estrogen may reflect the medication, not GH status; switching formulation and retesting can clarify.

Acute illness. Critical illness, major surgery, and acute inflammation transiently suppress IGF-1. A value drawn during hospitalization or shortly after major illness is not a reliable basis for diagnosing GH deficiency.

Weight extremes. Obesity is associated with a degree of GH resistance and lower circulating IGF-1 relative to GH secretion; IGF-1 sometimes rises after weight loss because hepatic sensitivity to GH improves, not necessarily because GH secretion itself changed [4].

A single abnormal value is a data point, not a diagnosis. Two values pointing the same direction, drawn on the same assay, are what actually justify further workup or a treatment change.

Evidence boundary: what is established, what is not

Established: IGF-1 is a validated, guideline-recommended screening marker for suspected GH excess (acromegaly) and GH deficiency, and it is the standard monitoring marker for GH and secretagogue therapy [2][8]. Age-adjusted reference ranges are real and necessary for correct interpretation [4][5]. Oral estrogen, acute illness, malnutrition, and liver disease are documented confounders [6][12].

Plausible but not proven: That deliberately targeting IGF-1 toward the middle of the age-adjusted range, rather than simply staying "in range," meaningfully changes long-term cancer or cardiovascular outcomes for an individual. The U-shaped mortality association is real at the population level [19], but it has not been shown that intervening on IGF-1 itself, as opposed to the underlying condition driving an abnormal value, changes an individual's risk.

Not established: That off-label GH-secretagogue peptides used for longevity or performance goals in people without diagnosed GH deficiency produce the same risk-benefit profile documented in FDA-approved-indication trials such as tesamorelin's lipodystrophy studies. That evidence does not currently exist for this use case, and readers considering these peptides off-label should treat the tesamorelin trial data as informative about mechanism, not as safety evidence for a different population and indication.

If you have symptoms suggestive of acromegaly (new ring or shoe size change, worsening sleep apnea, new jaw or bite changes) or symptoms suggestive of significant GH deficiency (unexplained fatigue with a known pituitary history, low bone density, or reduced exercise capacity), an abnormal IGF-1 warrants evaluation by an endocrinologist rather than self-directed peptide or supplement changes. Sudden severe headache with visual changes alongside a pituitary mass history is a reason for urgent, not routine, care.

Decision framework: what your IGF-1 result should actually trigger

This is not a substitute for clinical evaluation. It is a structured way to think about what a given result means before you or your clinician decide on next steps.

The recurring theme across every row: a lab report cannot tell you why your IGF-1 is where it is. The confounder check comes before the treatment decision, not after.